In preclinical models of NASH-induced HCC, the delivery of immunotherapy-targeting programmed death-1 (PD1), in fact, expanded activated CD8+PD1+ T-cells within tumors but did not lead to tumor regression, indicating that tumor immune surveillance was impaired. This evidence concerns the gene CD8A and hepatocellular carcinoma.